CN1308324C - 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物 - Google Patents

作为α－1肾上腺素能拮抗剂的喹唑啉衍生物 Download PDF

Info

Publication number
CN1308324C
CN1308324C CNB018165958A CN01816595A CN1308324C CN 1308324 C CN1308324 C CN 1308324C CN B018165958 A CNB018165958 A CN B018165958A CN 01816595 A CN01816595 A CN 01816595A CN 1308324 C CN1308324 C CN 1308324C
Authority
CN
China
Prior art keywords
methyl
amino
alkyl
phenyl
dimethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018165958A
Other languages
English (en)
Chinese (zh)
Other versions
CN1545510A (zh
Inventor
C·K·贝克尔
C·R·梅尔维尔
J·R·普菲斯特
X·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1545510A publication Critical patent/CN1545510A/zh
Application granted granted Critical
Publication of CN1308324C publication Critical patent/CN1308324C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB018165958A 2000-08-31 2001-08-23 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物 Expired - Fee Related CN1308324C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31
US60/229,503 2000-08-31

Publications (2)

Publication Number Publication Date
CN1545510A CN1545510A (zh) 2004-11-10
CN1308324C true CN1308324C (zh) 2007-04-04

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018165958A Expired - Fee Related CN1308324C (zh) 2000-08-31 2001-08-23 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物

Country Status (19)

Country Link
US (1) US6559153B2 (enExample)
EP (1) EP1315714B1 (enExample)
JP (1) JP3971299B2 (enExample)
KR (1) KR100602929B1 (enExample)
CN (1) CN1308324C (enExample)
AR (1) AR032475A1 (enExample)
AT (1) ATE309240T1 (enExample)
AU (2) AU9378801A (enExample)
BR (1) BR0113585A (enExample)
CA (1) CA2420177C (enExample)
DE (1) DE60114852T2 (enExample)
ES (1) ES2251512T3 (enExample)
GT (1) GT200100181A (enExample)
MX (1) MXPA03001777A (enExample)
PA (1) PA8527901A1 (enExample)
PE (1) PE20020407A1 (enExample)
UY (1) UY26919A1 (enExample)
WO (1) WO2002018348A2 (enExample)
ZA (1) ZA200301082B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341552T1 (de) * 2001-08-10 2006-10-15 Neuro Therapeutics Ltd Derivate morphinähnlicher opioidverbindungen
JP2005521728A (ja) * 2002-04-03 2005-07-21 オリオン コーポレーション ＣＮＳ関連疾患のためのα２−アドレナリン受容体アンタゴニストの使用
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
ATE440825T1 (de) * 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
DE602004020994D1 (de) * 2003-07-24 2009-06-18 Euro Celtique Sa Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
WO2006021345A2 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
BRPI0611537A2 (pt) * 2005-05-04 2010-09-21 Hoffmann La Roche (3,4-diidro-quinazolin-2-il) -(2-arilóxi-etil)-aminas tendo uma atividade sobre o receptor de 5-ht
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
WO2008036700A2 (en) * 2006-09-19 2008-03-27 3M Innovative Properties Company Templated metal oxide particles and methods of making
MX2010003927A (es) 2007-10-11 2010-04-30 Astrazeneca Ab Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
KR101851820B1 (ko) 2011-04-01 2018-06-04 아스트라제네카 아베 치료적 요법
SG11201401471PA (en) 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN110662541B (zh) * 2017-03-12 2023-02-10 王晓冬 多环胺作为阿片受体调节剂
WO2019088095A1 (ja) * 2017-11-02 2019-05-09 国立大学法人九州大学 鎮痛剤及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103738A (en) * 1995-12-23 2000-08-15 Pfizer Inc. Quinoline and quinazoline compounds useful in therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853479A4 (en) 1995-09-29 2001-04-11 Merck & Co Inc ALPHA 1B ADRENERGIC RECEPTOR ANTAGONISTS
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103738A (en) * 1995-12-23 2000-08-15 Pfizer Inc. Quinoline and quinazoline compounds useful in therapy

Also Published As

Publication number Publication date
PE20020407A1 (es) 2002-05-21
AR032475A1 (es) 2003-11-12
AU2001293788B2 (en) 2007-10-11
ATE309240T1 (de) 2005-11-15
CA2420177A1 (en) 2002-03-07
GT200100181A (es) 2002-05-23
KR100602929B1 (ko) 2006-07-20
WO2002018348A3 (en) 2002-07-11
EP1315714B1 (en) 2005-11-09
JP2004507527A (ja) 2004-03-11
KR20030022421A (ko) 2003-03-15
CA2420177C (en) 2008-07-08
PA8527901A1 (es) 2002-07-30
AU9378801A (en) 2002-03-13
ZA200301082B (en) 2004-05-07
BR0113585A (pt) 2003-07-29
EP1315714A2 (en) 2003-06-04
JP3971299B2 (ja) 2007-09-05
MXPA03001777A (es) 2003-06-04
US20020045614A1 (en) 2002-04-18
US6559153B2 (en) 2003-05-06
DE60114852T2 (de) 2006-07-27
UY26919A1 (es) 2002-02-28
WO2002018348A2 (en) 2002-03-07
ES2251512T3 (es) 2006-05-01
DE60114852D1 (de) 2005-12-15
CN1545510A (zh) 2004-11-10

Similar Documents

Publication Publication Date Title
CN1308324C (zh) 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物
CN1237060C (zh) 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物
CN1187342C (zh) 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
CN1142161C (zh) 作为5－ht4受体拮抗剂的二氢苯并二噁烯羧酰胺与酮衍生物
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1158256C (zh) 吡咯烷衍生物-ccr-3受体拮抗剂
CN1267423C (zh) 作为ip拮抗剂的取代的2－苯基氨基咪唑啉苯基酮衍生物
CN1178922C (zh) 取代的1-氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
CN1298391A (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1527816A (zh) 新的具有5-ht6受体亲和性的吲哚衍生物
CN1356987A (zh) 新型苯并咪唑衍生物和包括这些化合物的药物组合物
CN1671386A (zh) 作为mch选择性拮抗剂的取代苯胺基哌啶
CN1211572A (zh) 趋化细胞因子受体－3拮抗剂
CN1627945A (zh) 作为npy拮抗剂的喹啉衍生物
CN1564820A (zh) 用于治疗泌尿道疾病的杂环化合物
CN1701068A (zh) 新颖的化合物和它们的用途
CN1845908A (zh) 5－取代的喹唑啉酮衍生物
CN1845924A (zh) 芳基胺取代的喹唑啉酮化合物
CN1713908A (zh) 作为5－ht6－受体配体用于治疗中枢神经系统病症的氨基烷氧基吲哚
CN1296365C (zh) 咪唑啉基甲基芳烷基磺酰胺
CN1256334C (zh) 用作ip拮抗剂的烷氧基羰基氨基苯甲酸或烷氧基羰基氨基四唑基苯基衍生物
CN1599722A (zh) 作为毒蕈碱受体拮抗剂的4－哌啶基烷基胺衍生物
CN1280289C (zh) 用作ip拮抗剂的烷氧基羰基氨基杂芳基羧酸衍生物
CN101031554A (zh) 苯并嗪和喹喔啉衍生物及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070404